Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay
Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. H...
Saved in:
Published in | Biomolecules & therapeutics Vol. 23; no. 5; pp. 486 - 492 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
The Korean Society of Applied Pharmacology
01.09.2015
한국응용약물학회 |
Subjects | |
Online Access | Get full text |
ISSN | 2005-4483 1976-9148 1976-9148 2005-4483 |
DOI | 10.4062/biomolther.2015.041 |
Cover
Abstract | Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their inter-assay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery. |
---|---|
AbstractList | Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their interassay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug.
The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates.
Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery. KCI Citation Count: 9 Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their inter-assay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery. |
Author | Cha, Hey-Jin Seong, Won-Keun Kim, Hyung Soo Yun, Jae-Suk Han, Kyoung-Moon Lee, Yong-Moon Kim, Young-Hoon Shin, Ji-Soon Bae, Young-Ji |
AuthorAffiliation | 1 Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700 2 College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea |
AuthorAffiliation_xml | – name: 1 Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700 – name: 2 College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea |
Author_xml | – sequence: 1 givenname: Young-Hoon surname: Kim fullname: Kim, Young-Hoon organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 2 givenname: Young-Ji surname: Bae fullname: Bae, Young-Ji organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 3 givenname: Hyung Soo surname: Kim fullname: Kim, Hyung Soo organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 4 givenname: Hey-Jin surname: Cha fullname: Cha, Hey-Jin organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 5 givenname: Jae-Suk surname: Yun fullname: Yun, Jae-Suk organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 6 givenname: Ji-Soon surname: Shin fullname: Shin, Ji-Soon organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 7 givenname: Won-Keun surname: Seong fullname: Seong, Won-Keun organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea – sequence: 8 givenname: Yong-Moon surname: Lee fullname: Lee, Yong-Moon organization: College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea – sequence: 9 givenname: Kyoung-Moon surname: Han fullname: Han, Kyoung-Moon organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea, College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26336590$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002019384$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9UsFuEzEQtVARTQtfgIR85JJge23v-oIUotJGSgRC6dlydmcb01072N5K6ZkPr7eBFjhw8Yw0782b8bwzdOK8A4TeUjLjRLIPW-t736UdhBkjVMwIpy_QhKpSThXl1QmaMELElPOqOEVnMX4nRJZUyFfolMmikEKRCfq5BhOHAD24hH2Lr4beOLw4JF_vgu8Bf-WC4At3f8j50jVDnax3-JOJ0OCcrCGaztxbB9i4Bq99NPtgG8ALm4JJgDcBTBq7R3wdrbvBBq-GPuNjPUrOYzSH1-hla7oIb37Fc3T9-WKzuJquvlwuF_PVtOZCpSkFqDhpCS1MpUpDpIKSNxWrFJEtaxmRBS15RRtWkir_CBRbKgQDWlBGtrQpztH7Y18XWn1bW-2NfYw3Xt8GPf-2WWqqlBRVhn48QvfDtodmnDWYTufdehMOj8S_K87ucps7zYWQjJJnrX3wPwaISfc2r9x1xoEfoqYlUSXl-c3Qd39qPYn8vlIGFEdAHXyMAdonCCV69IJ-9oIevaCzFzJL_cOqbTLj-fLAtvsv9wEmJb38 |
CitedBy_id | crossref_primary_10_3390_medicina59020340 crossref_primary_10_3390_ht7040029 crossref_primary_10_1155_2021_9384663 crossref_primary_10_1186_s12991_017_0140_8 crossref_primary_10_1038_s41598_024_51781_6 crossref_primary_10_1016_j_dmpk_2019_08_006 crossref_primary_10_1080_00498254_2019_1588410 crossref_primary_10_1186_s13287_018_0910_5 crossref_primary_10_3390_pharmaceutics16111431 crossref_primary_10_1007_s12272_016_0748_2 crossref_primary_10_1016_j_bcp_2019_07_013 crossref_primary_10_3748_wjg_v25_i23_2846 crossref_primary_10_1016_j_ijpharm_2022_122282 |
Cites_doi | 10.1517/17425255.2.4.629 10.1080/08998280.2000.11927719 10.1007/s11626-008-9085-1 10.1016/j.ccc.2006.02.004 10.1016/j.pharmthera.2012.12.007 10.1007/978-1-62703-321-3_1 10.3109/10408449209145319 10.1016/j.taap.2004.01.010 10.1517/17425255.4.1.103 10.1097/00054725-200409000-00019 |
ContentType | Journal Article |
Copyright | Copyright © 2015, The Korean Society of Applied Pharmacology 2015 |
Copyright_xml | – notice: Copyright © 2015, The Korean Society of Applied Pharmacology 2015 |
DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
DOI | 10.4062/biomolther.2015.041 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1976-9148 2005-4483 |
EndPage | 492 |
ExternalDocumentID | oai_kci_go_kr_ARTI_199658 PMC4556210 26336590 10_4062_biomolther_2015_041 |
Genre | Journal Article |
GroupedDBID | --- 23N 5-W 5GY 8JR 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. F5P HYE HZB JDI KQ8 M48 OK1 PGMZT RPM NPM 7X8 5PM .UV ACYCR |
ID | FETCH-LOGICAL-c459t-1ee840f013a897a069e74d828906f2f206317481d2708015e3b1552e13120b1d3 |
IEDL.DBID | M48 |
ISSN | 2005-4483 1976-9148 |
IngestDate | Tue Nov 21 21:47:39 EST 2023 Thu Aug 21 18:19:46 EDT 2025 Fri Jul 11 03:29:37 EDT 2025 Thu Apr 03 07:04:05 EDT 2025 Thu Apr 24 23:12:37 EDT 2025 Tue Jul 01 04:15:27 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 5 |
Keywords | CYP Mesalazine Human hepatocytes Luminescent assay Mosapride citrate |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c459t-1ee840f013a897a069e74d828906f2f206317481d2708015e3b1552e13120b1d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Kyoung-Moon Han and Young-Hoon Kim have contributed equally to this work. G704-000363.2015.23.5.012 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2015.041 |
PMID | 26336590 |
PQID | 1709714709 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_199658 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4556210 proquest_miscellaneous_1709714709 pubmed_primary_26336590 crossref_primary_10_4062_biomolther_2015_041 crossref_citationtrail_10_4062_biomolther_2015_041 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-09-01 |
PublicationDateYYYYMMDD | 2015-09-01 |
PublicationDate_xml | – month: 09 year: 2015 text: 2015-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Biomolecules & therapeutics |
PublicationTitleAlternate | Biomol Ther (Seoul) |
PublicationYear | 2015 |
Publisher | The Korean Society of Applied Pharmacology 한국응용약물학회 |
Publisher_xml | – name: The Korean Society of Applied Pharmacology – name: 한국응용약물학회 |
References | (OOOMB4_2015_v23n5_486_010) 2004; 199 (OOOMB4_2015_v23n5_486_013) 2013; 138 (OOOMB4_2015_v23n5_486_012) 1992; 22 (OOOMB4_2015_v23n5_486_006) 2012; 50 (OOOMB4_2015_v23n5_486_002) 2005; 3 (OOOMB4_2015_v23n5_486_001) 2013; 987 (OOOMB4_2015_v23n5_486_007) 2006; 22 (OOOMB4_2015_v23n5_486_011) 2004; 10 (OOOMB4_2015_v23n5_486_003) 2006; 2 (OOOMB4_2015_v23n5_486_005) 2008; 44 (OOOMB4_2015_v23n5_486_004) 2008; 4 (OOOMB4_2015_v23n5_486_009) 2000; 13 (OOOMB4_2015_v23n5_486_008) 2005; 13 23333322 - Pharmacol Ther. 2013 Apr;138(1):103-41 15472525 - Inflamm Bowel Dis. 2004 Sep;10(5):626-31 16082059 - Top HIV Med. 2005 Jun-Jul;13(2):79-83 23475663 - Methods Mol Biol. 2013;987:1-9 15364537 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209 1616599 - Crit Rev Toxicol. 1992;22(1):1-21 16389357 - Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3 22541755 - Int J Clin Pharmacol Ther. 2012 Jul;50(7):524-31 16678003 - Crit Care Clin. 2006 Apr;22(2):329-45, vii 18427905 - In Vitro Cell Dev Biol Anim. 2008 May-Jun;44(5-6):129-34 18370862 - Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):103-20 16859410 - Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45 |
References_xml | – volume: 2 start-page: 629 year: 2006 ident: OOOMB4_2015_v23n5_486_003 publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425255.2.4.629 – volume: 13 start-page: 421 year: 2000 ident: OOOMB4_2015_v23n5_486_009 publication-title: Proc. (Bayl. Univ. Med. Cent.) doi: 10.1080/08998280.2000.11927719 – volume: 44 start-page: 129 year: 2008 ident: OOOMB4_2015_v23n5_486_005 publication-title: In Vitro Cell. Dev. Biol. Anim doi: 10.1007/s11626-008-9085-1 – volume: 22 start-page: 329 year: 2006 ident: OOOMB4_2015_v23n5_486_007 publication-title: Crit. Care Clin. doi: 10.1016/j.ccc.2006.02.004 – volume: 13 start-page: 79 year: 2005 ident: OOOMB4_2015_v23n5_486_008 publication-title: Top. HIV Med – volume: 138 start-page: 103 year: 2013 ident: OOOMB4_2015_v23n5_486_013 publication-title: Pharmacol. Ther doi: 10.1016/j.pharmthera.2012.12.007 – volume: 987 start-page: 1 year: 2013 ident: OOOMB4_2015_v23n5_486_001 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-62703-321-3_1 – volume: 22 start-page: 1 year: 1992 ident: OOOMB4_2015_v23n5_486_012 publication-title: Crit. Rev. Toxicol doi: 10.3109/10408449209145319 – volume: 50 start-page: 524 year: 2012 ident: OOOMB4_2015_v23n5_486_006 publication-title: Int. J. Clin. Pharmacol. Ther. – volume: 3 start-page: 9 year: 2005 ident: OOOMB4_2015_v23n5_486_002 publication-title: Pharmacologyonline – volume: 199 start-page: 193 year: 2004 ident: OOOMB4_2015_v23n5_486_010 publication-title: Toxicol. Appl. Pharmacol doi: 10.1016/j.taap.2004.01.010 – volume: 4 start-page: 103 year: 2008 ident: OOOMB4_2015_v23n5_486_004 publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425255.4.1.103 – volume: 10 start-page: 626 year: 2004 ident: OOOMB4_2015_v23n5_486_011 publication-title: Inflamm. Bowel Dis. doi: 10.1097/00054725-200409000-00019 – reference: 18427905 - In Vitro Cell Dev Biol Anim. 2008 May-Jun;44(5-6):129-34 – reference: 16082059 - Top HIV Med. 2005 Jun-Jul;13(2):79-83 – reference: 22541755 - Int J Clin Pharmacol Ther. 2012 Jul;50(7):524-31 – reference: 23333322 - Pharmacol Ther. 2013 Apr;138(1):103-41 – reference: 16859410 - Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45 – reference: 15364537 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209 – reference: 16389357 - Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3 – reference: 18370862 - Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):103-20 – reference: 15472525 - Inflamm Bowel Dis. 2004 Sep;10(5):626-31 – reference: 16678003 - Crit Care Clin. 2006 Apr;22(2):329-45, vii – reference: 23475663 - Methods Mol Biol. 2013;987:1-9 – reference: 1616599 - Crit Rev Toxicol. 1992;22(1):1-21 |
SSID | ssj0067156 |
Score | 2.0656269 |
Snippet | Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 486 |
SubjectTerms | Original 약학 |
Title | Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26336590 https://www.proquest.com/docview/1709714709 https://pubmed.ncbi.nlm.nih.gov/PMC4556210 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002019384 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Biomolecules & Therapeutics, 2015, 23(5), , pp.486-492 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKuXBBRby2hcpIPZLF7zQnBKtWBTWIQ1fqzXISm666TdpkV2I594d3xtndsqggcUksxY4Tj635xp75hpADhThABpk44ViiCs9hzWU8MaLkZWmK4CQGOOffzMlYfT3X51tklRV1OYDdg6Yd5pMat9Phz5vFR1jwgF-HoI7EBwxUb6aIl9BVSw8ZBrI_BtVk0BrL1fpYwaQ8pnON9Jtgl8iehuhvL9lQVY_qNjyEQv90pvxNOx3vkKdLWEk_9fPgGdny9XNym99vANIm0LhhT0eLWVNeIEsB_a40o0f1rwWUMYdHjHGgn0GxVRQKue_cNNJPU1dXNG86d91OKk9Hk8hpS89WXuodja4H1NHT-RU60uNnUhC9W7wg4-Ojs9FJssy6kJRKZ7OEew9GXwBo6A6z1DGT-VRVaJgxE0QQgGnAigGYK1JAm1x7WSCNm-eSC1bwSr4k23VT-9eEplVgJUAMLzHxn9OFZ14HBc2VZFUQAyJWA2zLJSU5ZsaYWjBNUCr2XioWpWJBKgPyft3oumfk-Hf1dyA5e1lOLDJp4_1HYy9bC_bCF4s-2PoQ6qzkamF14ZGJq30z7yxPkWNLwXVAXvVyXncqjJRGZ2xA0o0ZsK6A_W0-qScXkcFbaYCdnO3-36_skSdY7D3c3pDtWTv3bwESzYr9OM33417VHUE6DZw |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Measurement+of+Human+Cytochrome+P450+Enzyme+Induction+Based+on+Mesalazine+and+Mosapride+Citrate+Treatments+Using+a+Luminescent+Assay&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Kim%2C+Young-Hoon&rft.au=Bae%2C+Young-Ji&rft.au=Kim%2C+Hyung+Soo&rft.au=Cha%2C+Hey-Jin&rft.date=2015-09-01&rft.issn=2005-4483&rft.eissn=1976-9148&rft.volume=23&rft.issue=5&rft.spage=486&rft.epage=492&rft_id=info:doi/10.4062%2Fbiomolther.2015.041&rft.externalDBID=n%2Fa&rft.externalDocID=10_4062_biomolther_2015_041 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-4483&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-4483&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-4483&client=summon |